Relationship between polymorphism in the manganese superoxide dismutase gene and breast cancer

Eras-Erdogan, N.; Akbaş, Etem; Senli, H.; Kül, Seval; Çolak, Tahsin

doi:10.1016/j.mrgentox.2009.08.006

Cited by 16 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the results are also conflicting. Even for one risk factor, some of the studies show a significant risk modification, while others do not [6,11,20,21].…”

Section: Introductionmentioning

confidence: 99%

“…This finding has led to a number of case-control studies for illustration of its contribution to a variety of diseases [4,[11][12][13][14][15][16][17][18][19][20][21][22][23][24]. However, the results of investigation into its function in breast cancer are conflicting [6,11,13,14,21], implying that its effect may be modified by other risk factors. So far, the factors previously evaluated include menopausal status, use of oral contraceptives, use of hormone replacement therapy (HRT), vegetables and fruits intake, vitamin supplement, body mass index (BMI), etc.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Possible risk modifications in the association between MnSOD Ala-9Val polymorphism and breast cancer risk: subgroup analysis and evidence-based sample size calculation for a future trial

Chen

Pei²

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Manganese superoxide dismutase (MnSOD) has been identified as an important scavenger of reactive oxygen species (ROS), which can cause oxidative stress followed by breast cancer. A number of subsequent population-based studies have investigated the association between MnSOD Ala-9Val polymorphism and the risk of breast cancer. However, these studies have yielded conflicting results. This fact implies that the effect of MnSOD Ala-9Val polymorphism on the susceptibility to breast cancer may be modified by other risk factors. To provide a more definitive conclusion, a full meta-analysis combining and summarizing 16 studies was first performed using both traditional and Bayesian approaches. During this step, a recessive inheritance mode was determined after a biological justification. The capability of the Bayesian method was highlighted in the estimation of a pooled odds ratio and 95% confidence interval. As a result, no significant association was observed (OR = 0.978, CI = 0.914-1.046). Bayesian meta-regression and subgroup analysis were then conducted to find possible risk modifications by other factors, including menopausal status, ethnicity effect, use of oral contraceptives, use of hormone replacement therapy, fruits and vegetables intake, vitamin supplement, and body mass index. While the power of most subgroups may be insufficient to make a statistical statement, an evidencebased sample size calculation based upon updated metaanalysis was performed to power a future trial. For example, approximately 5,000 subjects are required for a new Asian study (2,500 cases and 2,500 controls) to achieve 80% power.

show abstract

“…However, the results are also conflicting. Even for one risk factor, some of the studies show a significant risk modification, while others do not [6,11,20,21].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Possible risk modifications in the association between MnSOD Ala-9Val polymorphism and breast cancer risk: subgroup analysis and evidence-based sample size calculation for a future trial

Chen

Pei²

2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…A meta-analysis suggested that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in prostate cancer development [9]. Several original studies have reported the role of MnSOD Val16Ala polymorphism in breast cancer risk [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28], but the results are inconclusive, partially because of the possible small effect of the polymorphism on breast cancer risk and the relatively small sample size in each of published studies. Therefore, we performed this meta-analysis to derive a more precise estimation of these associations.…”

Section: Introductionmentioning

confidence: 99%

Lack of association between MnSOD Val16Ala polymorphism and breast cancer risk: a meta-analysis involving 58,448 subjects

Qiu

Yao

Chen

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Published data on the association between MnSOD Val16Ala polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the MnSOD Val16Ala polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (Val/Ala vs. Val/Val, Ala/Ala vs. Val/Val), dominant model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val), respectively. A total of 32 studies including 26,022 cases and 32,426 controls were involved in this meta-analysis. Overall, no significant associations were found between MnSOD Val16Ala polymorphism and breast cancer risk when all studies pooled into the meta-analysis (Val/Ala vs. Val/Val: OR = 1.022, 95% CI = 0.981-1.064; Ala/Ala vs. Val/Val: OR = 1.006, 95% CI = 0.934-1.083; dominant model: OR = 1.013, 95% CI = 0.962-1.066; and recessive model: OR = 0.985, 95% CI = 0.931-1.042). In the subgroup analysis by ethnicity or study design, still no significant associations were found for all comparison models. In conclusion, this meta-analysis suggests that the MnSOD Val16Ala polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding.

show abstract

“…In the same year, Kocabaş et al (35) also carried out another case-control study, including 103 patients and 84 controls, demonstrating a similar result to Bergman et al (32); however, no significant difference about the risk of allele T and C was observed. Furthermore, the majority of other publications suggested that the SOD2 Val-16Ala could not increase or decrease breast cancer risk and survival (26)(27)(28)(29)(30)(31)33,34,(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50).…”

Section: Discussionmentioning

confidence: 99%

There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival

Wang

Liu

Zhou

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Breast cancer is the most common diagnosed cancer among females worldwide. Superoxide dismutase 2 (SOD2), an antioxidant enzyme, may break the balance between the oxidant and antioxidant system to induce various diseases. The present study aimed to clarify the association between the SOD2 Val-16Ala polymorphism and breast cancer risk or survival. Thus, a meta-analysis of the relevant articles retrieved from PubMed and EMBASE databases was conducted to illuminate the association with odd ratios (ORs) or hazards ratios (HRs). A total of 26 eligible publications (n=38,008) were available in risk analysis and eight publications ( The present meta-analysis indicated that there was no significant relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival, although in Caucasian patients, the SOD2 TT genotype may marginally decrease the risk of breast cancer in comparison to the CT + CC genotype.

show abstract

Relationship between polymorphism in the manganese superoxide dismutase gene and breast cancer

Cited by 16 publications

References 28 publications

Possible risk modifications in the association between MnSOD Ala-9Val polymorphism and breast cancer risk: subgroup analysis and evidence-based sample size calculation for a future trial

Possible risk modifications in the association between MnSOD Ala-9Val polymorphism and breast cancer risk: subgroup analysis and evidence-based sample size calculation for a future trial

Lack of association between MnSOD Val16Ala polymorphism and breast cancer risk: a meta-analysis involving 58,448 subjects

There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival

Contact Info

Product

Resources

About